AKRO NASDAQ
Akero Therapeutics, Inc.
1W: +0.3%
1M: +1.1%
3M: +26.4%
1Y: +84.0%
3Y: +20.2%
5Y: +93.0%
$54.65
Last traded 2025-12-09 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+37.9% ▲
Operating Income
-$285M
-65.1% ▼
Net Income
-$252M
-66.1% ▼
EPS (Diluted)
$-3.75
-29.8% ▼
EBITDA
-$247M
-92.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $213K | $0 | $0 | $0 | $0 |
| Gross Profit | -$213K | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $65M | $82M | $85M | $142M | $247M |
| SG&A Expenses | $15M | $19M | $30M | $31M | $38M |
| Operating Expenses | $80M | $101M | $115M | $173M | $285M |
| Operating Income | -$80M | -$101M | -$115M | -$173M | -$285M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $739K | $3M | $5M |
| Income Before Tax | -$79M | -$101M | -$112M | -$152M | -$252M |
| Tax Expense | -$17K | $0 | $0 | $0 | $0 |
| Net Income | -$79M | -$101M | -$112M | -$152M | -$252M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.52 | $-2.89 | $-2.87 | $-2.89 | $-3.75 |
| EBITDA | -$79M | -$101M | -$111M | -$149M | -$247M |
| Shares Outstanding | 31M | 35M | 39M | 53M | 67M |